An interventional study of Hemopill and OGD in Melena, Gastrointestinal Bleeding and Hematemesis, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong — 4 open to participants now, 4 under way, none of them phase 3. Gastrointestinal Hemorrhage · Chinese University of Hong Kong.
Among the 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 17th registered.
338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.
Browse Gastrointestinal Hemorrhage studies →4 of the 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong are open now, in 5 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in China
Ages 18+
Chinese University of Hong Kong · Sites in China, Hong Kong, Thailand
Ages 18+
Chinese University of Hong Kong · Sites in Australia, Hong Kong, Singapore
Ages 18–99
By country, each count listing its studies:
Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 193 is above the median of 98 across 210 interventional studies indexed under Gastrointestinal Hemorrhage.
Median enrollment 216 across the 15 interventional studies, 2,505 across the 2 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06715293Chinese University of Hong KongA Study to Evaluate the Performance of a Wireless Optical Sensor Capsule in Detection of UGIB | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Gastrointestinal Hemorrhage by Chinese University of Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Upper gastrointestinal bleeding (UGIB) is a common and potentially lethal medical emergency, which requires hospitalization and healthcare resources. Despite the changing epidemiology and advancement of endoscopic therapy in the recent decade, the all-cause mortality of UGIB remains high (>2%). An accurate risk stratification is necessary to triage patients into low- or high-risk groups, in order to inform clinicians for the necessity and timing of urgent endoscopy. However, existing pre-endoscopy risk scores, such as the Glasgow-Blatchford score (GBS), Rockall score and AIMS65 score, are suboptimal in predicting relevant clinical outcomes. An alternative strategy for risk stratification is urgently warranted in patients with UGIB to guide the next step of management.
In a pre-clinical study, the sensitivity and specificity of HemoPill® prototype were 95% and 87.5% respectively, when the sensors were positioned close to the bleeding point. Furthermore, several human clinical studies have proven the feasibility and accuracy of HemoPill® in healthy volunteers and patients with suspected UGIB. Capsule ingestion was well tolerated with no device-related adverse event or capsule retention. All patients with negative HI were found to have no active endoscopic bleeding (true negative, 100%, 17/17). In patients with bleeding >20ml, true positive HI signals were detected (100%, 2/2) In a retrospective multi-center study, 61 patients with suspected UGIB were recruited to use HemoPill®. Among the capsule-positive cases, subsequent endoscopy confirmed active bleeding in 57% (20/35) of them. None of the capsule-negative patients rebled (0%, 0/25), which prevented unnecessary emergent endoscopy in 72% of them (18/25).
From December 2023 to February 2024, the investigator conducted a pilot study and screened 51 adult subjects with symptoms and signs of suspected UGIB in Prince of Wales Hospital. Among them, the investigator recruited 20 eligible subjects to receive HemoPill® examination before oesophago-gastro-duodenoscopy (OGD). The overall sensitivity was 80% with a negative predictive value of 87.5%. The area-under-receiver-operating-characteristic curve was 0.633.
The pilot data demonstrated a huge potential for this novel, non-invasive, easy-to-use device as UGIB screening in the real-world. A large-scale, prospective validation study will be conducted to evaluate the diagnostic performance of the new generation HemoPill® acute capsule in UGIB.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemopill to detect the presence of active bleeding in the upper GI tract
Device: Hemopill · Procedure: OGD
ogd will be performed to compare the results with that of the hemopill
Device: Hemopill · Procedure: OGD
Hemopill will be swallowed to detect the presence of active bleeding in the upper GI tract
OGD will be performed to compare the results of the hemopill
Presence of active bleeding
Presence of active bleeding, old blood or potential bleeding sources during OGD examination, which warrants endoscopic haemostatic treatment.
Time frame: during OGD examination
Technical success rate
Technical success rate
Time frame: during OGD examination
Adverse event rate
Adverse event rate
Time frame: 30days post study procedure
Capsule retention rate
Capsule retention rate
Time frame: 30days post study procedure
Time from Hemopill acute capsule ingestion to a positive HI signal
Time from Hemopill acute capsule ingestion to a positive HI signal
Time frame: during OGD examination
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.
Of 63 non-industry interventional studies with no phase under Gastrointestinal Hemorrhage, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's planned 23 months is below that.
Counting every sponsor, half of 73 studies reached it within 22 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →